Researchers used a cohort of 756 adults with type 2 diabetes and found that receiving three text messages, an email message and a 10- to 15-minute phone call weekly for three months led to an A1C reduction from 8.4% to 7.4% and an average weight loss of 4.9 pounds, with similar results at 12 months. The findings, presented at the American Association of Clinical Endocrinologists annual meeting, showed that the digital health coaching program also resulted in an increased number of patients receiving eye and annual foot exams.
Patients with type 2 diabetes and obesity who took 10 mg of dapagliflozin daily for 12 weeks significantly reduced their plasma hepcidin concentrations from 265 ng/mL to 215 ng/mL and A1C levels from 7.1% to 6.7%, according to a study presented at the American Association of Clinical Endocrinologists annual meeting. Researchers recruited 22 patients, mean age of 62.1, and found that the dapagliflozin group also experienced an increase in hemoglobin and hematocrit concentrations, which wasn't seen in the placebo group.
Data from a study presented at the American Association of Clinical Endocrinologists annual meeting showed use of Valeritas' V-Go wearable insulin delivery device in patients with type 2 diabetes led to significant improvements in glycemic control and a reduction in the percentage of patients who had poorly controlled diabetes or were at high risk for long-term complications. A second study showed use of the device also was tied to a 35% increase in the average time spent in-range for patients taking at least three insulin injections daily.
The number of people with an ideal cardiovascular health score, based on seven lifestyle and biological measures, decreased from 8.5% to 5.9% from 1991 to 2008, according to a study in the Journal of the American Heart Association. Researchers said the decrease was due mainly to poorer scores for body mass index, blood pressure, blood glucose and cholesterol.
An article in Drug Topics suggests pharmacists advise Muslim patients who will fast during Ramadan about their medications and medication regimen, especially those with diabetes. "It is important for pharmacists to ask patients if they are considering fasting and engage in the conversation about safety and necessary adjustments, rather than restricting their intervention to patients who ask," said Wasem Alsabbagh of the School of Pharmacy at the University of Waterloo in Canada.
A study in Obstetrics & Gynecology showed that 76.8% of teen and young adult women said they were highly satisfied with intrauterine device insertion, while 83.2% believed that the IUD was worth the discomfort and 67.4% reported they would recommend the procedure to a friend. The findings also showed reduced odds of high overall satisfaction among adolescents, compared with young adults, and those who had never had a gynecologic examination, compared with those who had.
Norwegian researchers found that children who screened negative for autism spectrum disorder at age 18 months but later received ASD diagnoses had delayed communication, motor and social skills at screening age, compared with those without later ASD diagnoses, while girls in the false-negative group had lower social fearfulness than girls in the true-negative group or boys in the false-negative group. The findings in Pediatrics may help in the development of better ASD screening methods to avoid false-negative results, researchers said.
Children with X-linked hypophosphatemia ages 1 to 4 and ages 5 to 12 who took burosumab had 59% and 61% improvement in total Thacher Rickets Severity Score, respectively, as well as better Radiographic Global Impression of Change scores at 40 weeks, researchers reported at the American Association of Clinical Endocrinologists annual meeting. The findings also tied burosumab to improved serum calcitriol and phosphorus levels.
The PDD Blue Light Flexible Video Cytoscopy System has been launched by Karl Storz for use in the detection of bladder cancer. The release followed the recent FDA approval of a supplemental new drug application and a premarket approval supplement to add use of the cytoscopy system to the indication of the company's Blue Light Cystoscopy with Cysview.
Patients with malignant pheochromocytomas and paragangliomas had significantly reduced tumors in the lungs, liver and lymph nodes, significantly increased progression-free survival, better blood pressure and diabetes remission after receiving cabozantinib, researchers reported at the American Association of Clinical Endocrinologists' annual meeting. The findings also showed that cabozantinib stabilized disease among five of eight patients with predominant bone metastases on FDG-PET scans and was well-tolerated among all patients.
- Page 1